Charles River Laboratories Intl. (NYSE:CRL)‘s stock had its “hold” rating reaffirmed by equities researchers at Credit Suisse Group in a research note issued to investors on Thursday. They currently have a $108.00 price objective on the medical research company’s stock. Credit Suisse Group’s target price indicates a potential downside of 2.09% from the stock’s previous close.

A number of other research firms also recently commented on CRL. ValuEngine downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. SunTrust Banks upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and increased their price objective for the stock from $107.66 to $125.00 in a research note on Wednesday. Zacks Investment Research downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Monday, November 13th. Argus started coverage on shares of Charles River Laboratories Intl. in a research note on Wednesday, December 13th. They set a “buy” rating and a $120.00 price objective for the company. Finally, Royal Bank of Canada set a $116.00 price objective on shares of Charles River Laboratories Intl. and gave the stock a “hold” rating in a research note on Tuesday. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Charles River Laboratories Intl. presently has a consensus rating of “Buy” and a consensus target price of $114.85.

Charles River Laboratories Intl. (NYSE CRL) opened at $110.31 on Thursday. Charles River Laboratories Intl. has a one year low of $86.25 and a one year high of $119.05. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. The company has a market cap of $4,830.40, a PE ratio of 26.90, a PEG ratio of 1.50 and a beta of 0.74.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Tuesday, February 13th. The medical research company reported $1.40 EPS for the quarter, topping the Zacks’ consensus estimate of $1.26 by $0.14. Charles River Laboratories Intl. had a net margin of 10.72% and a return on equity of 26.58%. The company had revenue of $478.50 million during the quarter, compared to the consensus estimate of $475.02 million. During the same period in the prior year, the business posted $1.21 EPS. The company’s quarterly revenue was up 2.5% on a year-over-year basis. research analysts anticipate that Charles River Laboratories Intl. will post 5.14 earnings per share for the current year.

In other news, Director C Richard Reese sold 10,227 shares of the company’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $102.40, for a total value of $1,047,244.80. Following the sale, the director now directly owns 51,444 shares of the company’s stock, valued at approximately $5,267,865.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Robert J. Bertolini sold 3,609 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $110.22, for a total transaction of $397,783.98. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 195,673 shares of company stock worth $2,644,046. 2.20% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of CRL. TimesSquare Capital Management LLC raised its holdings in shares of Charles River Laboratories Intl. by 181.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 915,600 shares of the medical research company’s stock valued at $100,212,000 after purchasing an additional 589,900 shares during the period. Mackenzie Financial Corp raised its holdings in shares of Charles River Laboratories Intl. by 81.7% in the 3rd quarter. Mackenzie Financial Corp now owns 928,796 shares of the medical research company’s stock valued at $100,329,000 after purchasing an additional 417,739 shares during the period. APG Asset Management N.V. raised its holdings in shares of Charles River Laboratories Intl. by 261.2% in the 4th quarter. APG Asset Management N.V. now owns 368,800 shares of the medical research company’s stock valued at $33,615,000 after purchasing an additional 266,700 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in shares of Charles River Laboratories Intl. by 147.8% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 424,480 shares of the medical research company’s stock valued at $46,459,000 after purchasing an additional 253,180 shares during the period. Finally, Carillon Tower Advisers Inc. bought a new stake in shares of Charles River Laboratories Intl. in the 4th quarter valued at about $27,389,000. 97.13% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Charles River Laboratories Intl. (CRL) Earns “Hold” Rating from Credit Suisse Group” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/02/15/charles-river-laboratories-intl-crl-earns-hold-rating-from-credit-suisse-group.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.